



Session: 3b. Resistance Surveillance & Epidemiology: Gram-negatives

Presentation Number: 01030

Please access this presentation by
scanning the QR code or via


<http://tago.ca/eccmidXX>




Epidemiology of *Escherichia coli* Surveillance Isolates Causing Urinary Tract Infections in Europe and *In Vitro* Activity of Gepotidacin (2019-2020)

RE Mendes¹; S. J. Ryan Arends¹; J. H. Kimbrough¹; D Butler²; N Scangarella-Oman²; M Castanheira¹


¹JMI Laboratories, North Liberty, Iowa, USA; ²GlaxoSmithKline plc., Collegeville, Pennsylvania, USA



-
- Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action, which confers activity against most strains of target pathogens, such as *Escherichia coli*, *Staphylococcus saprophyticus*, and *Neisseria gonorrhoeae*, including those resistant to current antibiotics.
 - This study evaluated the epidemiology of *E. coli* causing UTI in patients seen in Europe and the activity of gepotidacin and comparators ag77



Conclusions



- Gepotidacin demonstrated potent activity against non-ESBL and ESBL, and various characterized *E. coli* subsets, including the resistant ST131 O25(b):H4 clone.
- These data support the clinical development of gepotidacin as a treatment option for UTI caused by *E. coli* including when other oral treatment options are limited due to resistance.

Disclosures

This study at JMI Laboratories was supported by GlaxoSmithKline. JMI Laboratories received compensation fees for services in relation to preparing the poster

This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under OTA Agreement No. HHSO100201300011C

Contact

Rodrigo E. Mendes, Ph.D.
JMI Laboratories
345 Beaver Creek Centre, Suite A
North Liberty, Iowa 52317
rodrigo-mendes@jmilabs.com